Lantheus to Divest CDMO Business and New Jersey Plant to PharmaLogic
LNTH has more than doubled off its 52-week low of $50.155.
Summary
Lantheus agreed to sell its contract development and manufacturing organization business and its Springfield, N.J., manufacturing facility to PharmaLogic under a definitive agreement entered into November 8, 2026, a move that expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies. The sale agreement includes a long-term supply deal under which PharmaLogic's Agilera unit will make lutetium Lu 177 dotatate for Lantheus, with transition services after closing. The deal sheds non-core manufacturing assets while the company is mid-flight on its $8 billion acquisition by Curium, which shareholders approved October 14 and which remains under FTC review after a Second Request. Terms were not disclosed, so the financial impact is unclear, but a divestiture of this type typically simplifies the asset base ahead of the Curium combination. The move follows a Q3 print showing revenue of $389.9 million (+1.5%) and GAAP EPS down 19.5% to $0.33 on impairment and milestone charges.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The PharmaLogic sale agreement includes a long-term supply deal under which PharmaLogic's Agilera unit will make lutetium Lu 177 dotatate for Lantheus, with transition services after closing.
- Definitive agreement with PharmaLogic Holdings Corp. entered into November 8, 2026.
At the time of this announcement, LNTH was trading at $101.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $50.16 to $111.86. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.